BSE · 531541
Kobo Biotech Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹103 Cr with net profit ₹-35 Cr — a -33.66% net margin, versus 3.46% the period before.
Shareholding
As of 2026-06-30
- Promoter44.95%
- Public55.05%
- DII0%
7,734 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 5.02× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 0 · ESM · ESM 2. Trading may carry price bands, periodic call auction or higher margins.
- 52-week range spans 5.02× (₹1.99 to ₹9.99) — an unusually wide band.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #87 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,83,106 Cr | 38.87 | 5.78 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,18,979 Cr | 214.38 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,770 Cr | 20.57 | 4.12 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,080 Cr | 19.53 | 4.95 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,06,574 Cr | 52.9 | 6.54 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,003 Cr | 87.79 | 18.11 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,503 Cr | 431.77 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,051 Cr | 99.93 | 2.43 | 9.25% | 10.5% |
| Alkem Laboratories Ltd. | ₹69,850 Cr | 295.5 | 5.05 | 16.66% | 15.65% |
| Biocon Ltd. | ₹68,718 Cr | 536.65 | 2.02 | 1.14% | 2.3% |
| Kobo Biotech Limited(this company) | ₹20 Cr | — | — | 3.71% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashKobo Biotech Limited (531541) operates with a market capitalization of Rs 22 Cr. The company has not specified its business activities. Kobo Biotech Limited is currently under GSM and ESM surveillance measures.
Positives
- +Promoter holding of 44.95% is consistent with no pledges reported, indicating no immediate distress or concerns regarding promoter stake leverage.
Negatives
- −The company has reported no revenue (Rs 0 Cr) for the last six consecutive quarters, ending June 2024.
- −Kobo Biotech Limited has a negative book value of Rs -57.98 per share.
- −The debt-to-equity ratio of 3.38 is high, indicating significant leverage.
- −The company has a negative Return on Capital Employed (ROCE) of -72.69%, suggesting inefficient capital utilization.
- −Kobo Biotech Limited is currently under GSM and ESM surveillance measures, indicating regulatory concerns.
Financial Performance
The company has reported no revenue across its latest quarterly results. For the quarter ending June 2024, revenue was Rs 0 Cr, with a net loss of Rs -1.33 Cr. Similar figures were observed in March 2024, with Rs 0 Cr revenue and a net loss of Rs -1.26 Cr. This trend extends to previous quarters, such as December 2023, September 2023, June 2023, and March 2023, all showing Rs 0 Cr revenue and net losses ranging from Rs -1.23 Cr to Rs -1.79 Cr.
Profitability & Returns
Kobo Biotech Limited's profitability is negative, with a profit margin of 0%. The Return on Capital Employed (ROCE) is -72.69%, indicating inefficiency in using capital to generate profits. However, the Return on Equity (ROE) is 370.84%, which contrasts with the other profitability metrics, suggesting potential impacts from equity structure or specific accounting considerations.
Balance Sheet
The company carries a debt-to-equity ratio of 3.38. The book value per share is negative at Rs -57.98, indicating that liabilities exceed assets. No annual balance sheet data is available to provide a comprehensive view of the company's financial position.
Ownership & Pledges
Public shareholding stands at 55.05%. Institutional holding, specifically by DIIs, is negligible at 0.0004%, with no FII holding. There are no pledged shares by the promoters.
Regulatory & Surveillance
Kobo Biotech Limited is subject to surveillance under both the Graded Surveillance Measure (GSM) and Enhanced Surveillance Measure (ESM) frameworks. Specifically, it is categorized under 'GSM' and 'ESM 2', indicating heightened monitoring by regulatory bodies due to concerns regarding price volatility or other irregularities.
Data as of — price: 2026-07-30 · financials: Mar 15 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.